Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure

被引:21
|
作者
Huang, Dong-Hui [1 ]
Sun, Hao [1 ]
Shi, Jing-Pu [1 ]
机构
[1] China Med Univ, Dept Clin Epidemiol & Evidence Based Med, Inst Cardiovasc Dis, Hosp 1, Shenyang 110001, Liaoning, Peoples R China
关键词
Biomarker; Diagnosis; Heart Failure; Meta-analysis; Soluble Suppression of Tumorigenicity-2; RECEPTOR FAMILY-MEMBER; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; EJECTION FRACTION; PROGNOSTIC UTILITY; ACUTE DYSPNEA; ST2; BIOMARKERS; ASSOCIATION; GALECTIN-3;
D O I
10.4103/0366-6999.177000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. Methods: We searched PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database from inception to April 2015. Studies that investigated the diagnostic role of sST2 for HF were reviewed. The numbers of true-positive, false-positive, false-negative, and true-negative results were extracted to calculate pooled diagnostic odds ratio (DOR) with 95% confidence interval (CI) and the summary receiver operating characteristic curve and area under the curve (AUC). The Spearman correlation coefficient was used to check the threshold effect. The Cochran Q statistic (P < 0.05) and the inconsistency index (I-2 > 50%) were used to assess the nonthreshold effect. Meta-regression was conducted to explore the source of heterogeneity; subgroup analysis showed the results in different subgroups. Finally, the Deeks' test was performed to assess the publication bias. Results: Nine articles including 10 studies were included in the meta-analysis. The pooled sensitivity was 0.84 (95% CI: 0.81-0.86), and pooled specificity was 0.74 (95% CI: 0.72-0.76). The summary DOR was 8.49 (95% CI: 4.54-15.86), and AUC was 0.81 (standard error: 0.03). The Spearman correlation coefficient identified the nonsignificant threshold effect (coefficient = 0.49, P = 0.148), but the nonthreshold effect heterogeneity was significant (Cochran Q = 58.52, P < 0.0001; I-2 = 84.6%). Meta-regression found that characteristics of controls might be the suggestive source of nonthreshold effect heterogeneity (P = 0.095). Subgroup analysis found that DOR was 5.65 and 7.86, respectively for the controls of hospital patients and healthy populations. Deeks' test demonstrated that there was no publication bias (P = 0.616). Conclusion: The meta-analysis illustrated that sST2 might play a role in diagnosing HF.
引用
收藏
页码:570 / 577
页数:8
相关论文
共 50 条
  • [21] Suppression of tumorigenicity-2 (ST2) is a promising biomarker in heart transplantation
    Galeone, Antonella
    Salem, Joe-Elie
    Lebreton, Guillaume
    Coutance, Guillaume
    Nguyen, Lee
    Hulot, Jean Sebastien
    Atassi, Fabrice
    Bega, Marco
    Leprince, Pascal
    Varnous, Shaida
    CLINICAL TRANSPLANTATION, 2022, 36 (05)
  • [22] Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis
    Dong, Guoqi
    Chen, Hao
    Zhang, Hongru
    Gu, Yihuang
    CARDIOLOGY, 2021, 146 (04) : 433 - 440
  • [23] Genetic Regulation Of Soluble Suppression Of Tumorigenicity-2 Expression In Acute Respiratory Distress Syndrome
    Chen, C. -Y.
    Barnett, I.
    Bajwa, E.
    Wei, Y.
    Wang, Z.
    Sul, L.
    Christiani, D. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [24] Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis
    Zhang, Ying
    Fan, Zixu
    Liu, Hua
    Ma, Jianwei
    Zhang, Min
    CORONARY ARTERY DISEASE, 2020, 31 (07) : 628 - 635
  • [25] Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2
    Gerber, Yariv
    Weston, Susan A.
    Enriquez-Sarano, Maurice
    Jaffe, Allan S.
    Manemann, Sheila M.
    Jiang, Ruoxiang
    Roger, Veronique L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10):
  • [26] Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia
    Kanninen, Tomi
    Jung, Eunjung
    Gallo, Dahiana M.
    Diaz-Primera, Ramiro
    Romero, Roberto
    Gotsch, Francesca
    Suksai, Manaphat
    Bosco, Mariachiara
    Chaiworapongsa, Tinnakorn
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2023, 36 (01):
  • [27] Serum Cardiac Biomarkers in Asymptomatic Hemodialysis Patients: Role of Soluble Suppression of Tumorigenicity-2
    Mancianti, Nicoletta
    Maresca, Barbara
    Palladino, Marco
    Salerno, Gerardo
    Cardelli, Patrizia
    Mene, Paolo
    Barberi, Simona
    BLOOD PURIFICATION, 2022, 51 (02) : 155 - 162
  • [28] Soluble suppression of tumorigenicity-2 predicts pneumonia in patients with inhalation injury: Results of a pilot study*
    Ruiz-Castilla, Mireia
    Dos Santos, Bruce
    Vizcaino, Claudia
    Baena, Jacinto
    Guilabert, Patricia
    Marin-Corral, Judith
    Masclans, Joan R.
    Roca, Oriol
    Barret, Juan P.
    BURNS, 2021, 47 (04) : 906 - 913
  • [29] Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure
    Miller, Wayne L.
    Saenger, Amy K.
    Grill, Diane E.
    Slusser, Joshua P.
    Bayes-Genis, Antoni
    Jaffe, Allan S.
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (04) : 249 - 255
  • [30] Soluble form of suppression of tumorigenicity-2 predicts clinical stability of inpatients with community-acquired pneumonia
    Zeng, Yifeng
    Xue, Mingshan
    Zhang, Teng
    Sun, Shixue
    Lin, Runpei
    Li, Ning
    Zheng, Peiyan
    Zhen, Yingjie
    Hu, Haisheng
    Zhang, Xiaohua Douglas
    Sun, Baoqing
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (21) : 2297 - 2306